
Dascena provides predictive machine learning models that identify patients at risk of acute conditions so clinicians can intervene earlier. The company develops and validates ML-based diagnostic and prognostic algorithms using de-identified patient data and electronic health record inputs. Its products are applied as clinical decision support, point-of-care diagnostics, and biopharma companion diagnostics for hospitals, health systems, and life sciences customers. Dascena operates as a healthcare AI vendor focused on predictive analytics, algorithm deployment, and EHR integration. The company targets clinical and pharmaceutical markets where earlier detection and risk stratification can improve outcomes and reduce downstream costs.

Dascena provides predictive machine learning models that identify patients at risk of acute conditions so clinicians can intervene earlier. The company develops and validates ML-based diagnostic and prognostic algorithms using de-identified patient data and electronic health record inputs. Its products are applied as clinical decision support, point-of-care diagnostics, and biopharma companion diagnostics for hospitals, health systems, and life sciences customers. Dascena operates as a healthcare AI vendor focused on predictive analytics, algorithm deployment, and EHR integration. The company targets clinical and pharmaceutical markets where earlier detection and risk stratification can improve outcomes and reduce downstream costs.
What they do: Predictive machine-learning models that identify patients at risk of acute conditions to enable earlier clinical intervention.
Flagship product: InSight sepsis detection algorithm (sepsis detection / early warning).
Top funding: $50,000,000 Series B (announced 2020-05-01).
Investors: Frazier Healthcare Partners, Longitude Capital, Euclidean Capital, National Institutes of Health (grant support).
Customers / use cases: Hospitals, health systems, and life sciences customers (clinical decision support, point-of-care diagnostics, companion diagnostics).
Early disease detection, sepsis detection, clinical risk stratification, and clinical decision support.
Biotechnology
$50,000,000
Participation noted from Longitude Capital and existing investor Euclidean Capital.
“Led by healthcare-focused growth investor Frazier Healthcare Partners with participation from Longitude Capital and Euclidean Capital; has received NIH grant support.”